Neuroblastoma Clinical Trials

73 recruiting

Neuroblastoma Trials at a Glance

102 actively recruiting trials for neuroblastoma are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 1 with 41 trials, with the heaviest enrollment activity in New York, Boston, and Dallas. Lead sponsors running neuroblastoma studies include National Cancer Institute (NCI), Giselle Sholler, and Memorial Sloan Kettering Cancer Center.

Browse neuroblastoma trials by phase

Treatments under study

About Neuroblastoma Clinical Trials

Looking for clinical trials for Neuroblastoma? There are currently 73 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 102 trials

Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled177 locationsNCT06172296
Recruiting

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

EsthesioneuroblastomaOlfactory Neuroblastoma
National Cancer Institute (NCI)525 enrolled1 locationNCT04755205
Recruiting
Phase 1

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Neuroblastoma
National Cancer Institute (NCI)34 enrolled1 locationNCT06995872
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting
Phase 2

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI)40 enrolled1 locationNCT06176989
Recruiting
Phase 2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Neuroblastoma
Giselle Sholler500 enrolled28 locationsNCT02559778
Recruiting
Phase 2

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Neuroblastoma
Giselle Sholler98 enrolled12 locationsNCT06540963
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Germ Cell TumorEwing SarcomaNeuroblastoma+3 more
New York Medical College30 enrolled1 locationNCT04308330
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Solid Tumor CancerHigh Risk NeuroblastomaMedulloblastoma
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 2

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

PheochromocytomaNeuroblastoma
Memorial Sloan Kettering Cancer Center200 enrolled1 locationNCT00107289
Recruiting
Phase 2

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma
Memorial Sloan Kettering Cancer Center94 enrolled7 locationsNCT06057948